Searchable abstracts of presentations at key conferences in endocrinology

ea0099ep210 | Pituitary and Neuroendocrinology | ECE2024

Pseudoacromegaly – a challenging entity in the endocrine clinic: why you need to know about it?

Marques Pedro , Sapinho Ines , Korbonits Marta

Introduction: Pseudoacromegaly encompasses a group of conditions in which patients have clinical features of acromegaly or gigantism, but no GH or IGF-1 excess. With systematically reviewing all published cases (n=76) of patients with pseudoacromegaly who were evaluated due to a clinical suspicion of acromegaly, we identified key distinguishing features which need to be recognized.Materials and Methods: A systematic search using the terms pseudo...

ea0081p486 | Thyroid | ECE2022

Resistance to methimazole in a patient with Graves’ disease

Roque Joao , Costa Cristiana , Marques Pedro , Reis Dinis

Introduction: Graves’ disease (GD) is caused by TSH receptor antibodies (TRAbs) which stimulate thyroid activity. Initial treatment usually relies on antithyroid drugs (ATDs), mainly methimazole, carbimazole or propylthiouracil (PTU). These drugs inhibit the enzyme thyroperoxidase, blocking the synthesis of T3 and T4. Definitive therapeutic options include radioactive iodine and total thyroidectomy which are usually reserved for patients who do not tolerate or respond to ...

ea0059ep78 | Neuroendocrinology and pituitary | SFEBES2018

Gigantism due to two different causes in the same family – AIP mutation-positive acromegaly and Marfan syndrome

Marques Pedro , Collier David , Barkan Ariel , Korbonits Marta

Germline aryl hydrocarbon receptor-interacting protein (AIP) mutations are responsible for 30% of pituitary gigantism cases. However, pathological accelerated growth and/or tall stature can be unrelated to the growth hormone (GH) axis, and may occur in isolation or as part of a syndrome, such as in Klinefelter, Marfan or Sotos syndromes. We report a five-generation kindred with two brothers with pituitary gigantism due to AIP mutation-positive GH-secreting pi...

ea0038p479 | Thyroid | SFEBES2015

Metastatic differentiated thyroid cancer with undetectable serum thyroglobulin: diagnostic, management and follow-up challenges

Marques Pedro , Ferreira Teresa , Salgado Lucilia , Cabrera Rafael , Leite Valeriano

Background: Serum thyroglobulin (Tg) is a reliable tumor marker in patients with differentiated thyroid carcinoma (DTC). Distant metastases of DTC, particularly in the lung, normally presents with higher levels of Tg, which is useful to follow the disease evolution. We describe a patient with DTC with lung metastases, with undetectable Tg and Tg-antibodies (TgAb).Clinical case: A 52-year-old woman underwent a subtotal thyroidectomy in 1993 because of a g...

ea0035p480 | Diabetes therapy | ECE2014

The role of continuous subcutaneous insulin infusion therapy in a case of Seip–Berardinelli congenital lipodystrophy

Marques Pedro , Carvalho Raquel , Macedo Daniel , Guerra Silvia

Introduction: Seip–Berardinelli congenital lipodystrophy (SBCL) is an extremely rare autosomal recessive disorder characterized by a congenital absence of adipose tissue. Hepatic steatosis, splenomegaly, skeletal muscle hypertrophy, hypertrophic cardiomyopathy, insulin-resistance and diabetes mellitus (DM) are some of the features of these patients.Case report: A 20-year-old caucasian-male patient was referred to pediatric endocrinology unit at 6-mo...

ea0081ep752 | Pituitary and Neuroendocrinology | ECE2022

Clinical presentation of non-functioning pituitary tumors: the experience at a tertiary care hospital in Portugal

Ines Alexandre Maria , Gomes Ana , Nobre Ema Lacerda , Marques Pedro , Bugalho Maria Joao

Introduction: Clinically non-functioning pituitary tumors (NFPTs) lack clinical or biochemical evidence of pituitary hormone excess. Their clinical presentation is heterogeneous, including mass effect-related symptoms and/or hypopituitarism, or even no symptoms in incidentally-detected NFPTs. We aimed to evaluate the clinical presentation spectrum of NFPTs in a cohort of patients managed at our hospital.Methods: Clinical, demographic, biochemical and ima...

ea0041ep720 | Male Reproduction | ECE2016

Adjustment of testosterone and dihydrotestosterone reference intervals to the male Portuguese population

Simoes-Pereira Joana , Prazeres Susana , Macedo Daniel , Silva-Vieira Margarida , Marques Pedro , Pereira Maria Conceicao

Introduction: In our practice we’ve been following some oncologic survivors patients with low-low/normal levels of testosterone who are asymptomatic. Aims: to determine the levels of total (TT) and free testosterones (FT) and dihydrotestosterone (DHT) in healthy men, in order to find the reference intervals (RI) adjusted to our population and compare them with those provided by the kit-producers (KP).Methods: We collected blood samples from 125 heal...

ea0035p631 | Female reproduction | ECE2014

The relationship between clinico-biochemical features in women with polycystic ovary syndrome and fertility treatment outcomes

Marques Pedro , Ferreira Florbela , Soares Ana , Nunes Joaquim , Sousa Sandra , Aguiar Ana , Calhaz-Jorge Carlos

Introduction: Polycystic ovary syndrome (PCOS) affects 5–8% of reproductive-age women. The morbidity related to PCOS may include insulin-resistance, type 2 diabetes mellitus (T2DM), obesity, hypertension, cardiovascular disease and infertility. We aimed to evaluate the clinico-biochemical characteristics of PCOS women and establish its relationship with fertility treatment outcomes.Methods: We reviewed clinical records of PCOS women (Rotterdam crite...

ea0070ep295 | Pituitary and Neuroendocrinology | ECE2020

Pre-operative full blood count, C-reactive protein and serum inflammation-based scores may predict aggressive or refractory disease in patients with pituitary adenomas

Marques Pedro , de Vries Friso , van Furth Wouter , Korbonits Marta , Biermasz Nienke , Pereira Alberto M

Introduction: Full blood count (FBC), C-reactive protein (CRP), albumin and serum inflammation-based scores reflect systemic inflammation and predict outcomes in oncological patients. While these are increasingly used in cancer, little is known in pituitary adenomas (PAs). We aimed to characterise FBC and inflammation-based scores in patients with PAs and investigate the usefulness of such parameters in predicting aggressive/refractory disease.Methods: W...

ea0032p1096 | Thyroid cancer | ECE2013

Radioactive iodine therapy in papillary thyroid carcinomas staged as T1

Marques Pedro , Macedo Daniel , Pereira Joana , Vieira Margarida , Leite Valeriano , Bugalho Maria

Introduction: 131I therapy in patients with papillary thyroid carcinomas (PTC) ≤2 cm and without extrathyroidal extension (T1) depends on multifactorial analysis: age, multifocality, histological criteria, lymph node or systemic metastasis. The study purposes were analyze PTC-T1 and compare the groups treated only with surgery vs combined therapy (surgery and 131I).Methods: Retrospective analysis of clinical files of PTC-T1 pa...